Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge
dc.contributor.author | Munro, A. | |
dc.contributor.author | Codde, J. | |
dc.contributor.author | Semmens, James | |
dc.contributor.author | Leung, Y. | |
dc.contributor.author | Spilsbury, Katrina | |
dc.contributor.author | Williams, Vincent | |
dc.contributor.author | Steel, N. | |
dc.contributor.author | Cohen, P. | |
dc.contributor.author | Pavicic, H. | |
dc.contributor.author | Westoby, V. | |
dc.contributor.author | O'Leary, Peter | |
dc.date.accessioned | 2017-01-30T11:20:57Z | |
dc.date.available | 2017-01-30T11:20:57Z | |
dc.date.created | 2015-07-16T06:21:50Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Munro, A. and Codde, J. and Semmens, J. and Leung, Y. and Spilsbury, K. and Williams, V. and Steel, N. et al. 2015. Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge. Australian Family Physician. 44 (1-2): pp. 64-68. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/10779 | |
dc.description.abstract |
Background - Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods - After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results - Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not ‘always’ receive a clear follow-up plan for patients after treatment of an HSIL. Discussion - GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL. | |
dc.publisher | The Royal Australian College of General Practitioners | |
dc.relation.uri | http://www.racgp.org.au/download/Documents/AFP/2015/January/February/research-munro.pdf | |
dc.subject | human papillomavirus [HPV] DNA | |
dc.subject | cytology | |
dc.subject | cervical disease | |
dc.subject | high-grade squamous intraepithelial lesion (HSIL) | |
dc.title | Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge | |
dc.type | Journal Article | |
dcterms.source.volume | 44 | |
dcterms.source.number | 1 | |
dcterms.source.startPage | 64 | |
dcterms.source.endPage | 68 | |
dcterms.source.issn | 0300-8495 | |
dcterms.source.title | Australian Family Physician | |
curtin.department | Centre for Population Health Research | |
curtin.accessStatus | Fulltext not available |